Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-term Investments (2016 - 2018)

Cumberland Pharmaceuticals' Short-term Investments history spans 7 years, with the latest figure at $8.3 million for Q4 2018.

  • On a quarterly basis, Short-term Investments rose 77.44% to $8.3 million in Q4 2018 year-over-year; TTM through Dec 2018 was $8.3 million, a 77.44% increase, with the full-year FY2018 number at $8.3 million, up 77.44% from a year prior.
  • Short-term Investments hit $8.3 million in Q4 2018 for Cumberland Pharmaceuticals, up from $4.7 million in the prior quarter.
  • Over the last five years, Short-term Investments for CPIX hit a ceiling of $15.6 million in Q4 2016 and a floor of $4.7 million in Q4 2017.
  • Historically, Short-term Investments has averaged $11.6 million across 5 years, with a median of $14.6 million in 2015.
  • Biggest five-year swings in Short-term Investments: plummeted 70.09% in 2017 and later soared 77.44% in 2018.
  • Tracing CPIX's Short-term Investments over 5 years: stood at $14.8 million in 2014, then dropped by 1.87% to $14.6 million in 2015, then increased by 7.26% to $15.6 million in 2016, then plummeted by 70.09% to $4.7 million in 2017, then surged by 77.44% to $8.3 million in 2018.
  • Business Quant data shows Short-term Investments for CPIX at $8.3 million in Q4 2018, $4.7 million in Q4 2017, and $15.6 million in Q4 2016.